PetVivo Inc. (PETVW)
0.05
0.02 (75.44%)
At close: Dec 06, 2024, 10:09 AM
Company Description
PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals.
Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses.
The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications.
PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
PetVivo Inc.
| Country | United States |
| IPO Date | Aug 11, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 20 |
| CEO | John Lai |
Contact Details
Address: 5251 Edina Industrial Boulevard Minneapolis, Minnesota United States | |
| Website | http://www.petvivo.com |
Stock Details
| Ticker Symbol | PETVW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001512922 |
| CUSIP Number | 716817119 |
| ISIN Number | US7168171194 |
| Employer ID | 99-0363559 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| John Lai | Chief Executive Officer, President & Director |
| Garry N. Lowenthal | Chief Financial Officer |
| April Boyce | Vice President of Sales & Marketing |
| John F. Dolan | General Counsel, Chief Business Development Officer & Secretary |
| Michael Eldred BA, MBA | Commercialization & Operations Advisor and Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | 4 | Filing |
| Apr 15, 2025 | 4 | Filing |
| Apr 08, 2025 | 8-K | Current Report |
| Apr 04, 2025 | SCHEDULE 13G | Filing |
| Mar 31, 2025 | 8-K/A | [Amend] Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |